Application of NETs synergistic CXC chemokine-receptor biological axis in relieving progress of aortic dissection

By blocking NETs and CXC chemokine-receptor biological axis, especially the CXCL3-CXCR2 biological axis, the prevention, treatment and relief problems of aortic dissection are solved, significantly reducing the mortality rate of aortic dissection and the maximum aortic diameter of aortic , promotes benign remodeling of the aorta.

CN118980821AInactive Publication Date: 2024-11-19ZHANGJIANG INST OF SCI & TECH FUDAN UNIV PUDONG SHANGHAI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411069202.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There are challenges in the prevention, treatment and mitigation of aortic dissection, especially in the case of adverse aortic remodeling and increased complications after surgery, and prior art is difficult to effectively predict and prevent aortic rupture and associated risk of mortality.

Method used

By blocking NETs and specific CXC chemokine-receptor biological axis, such as CXCL3-CXCR2 biological axis, pharmaceutical compositions are developed to inhibit NETs formation and the activity of CXC chemokine-receptor biological axis for prevention, treatment and relieve aortic dissection.

Benefits of technology

It effectively reduces the mortality rate of aortic dissection and the maximum aortic diameter, promotes benign aortic remodeling, and shows significant effects in preventing and treating aortic dissection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118980821A_ABST
    Figure CN118980821A_ABST
Patent Text Reader

Abstract

The invention discloses application of NETs in cooperation with a CXC chemotactic factor-receptor biological axis in relieving progress of aortic dissection, and belongs to the technical field of biological medicine. The invention creatively finds that specific inhibition of NETs formation and blocking of CXC chemotactic factor-receptor biological axis formation or expression have the effects of effectively relieving the progress of the dissection and reducing the death risk caused by aortic dissection rupture. Therefore, the NETs and the CXC chemokine-receptor biological axis can be used as potential therapeutic targets for preventing, treating and hindering the occurrence and development of the aortic dissection, and have a good effect and a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the application of NETs in coordinating with CXC chemokine-receptor biological axis in preventing, treating and alleviating the progression of aortic dissection. Background Art

[0002] Aortic dissection (AD, hereinafter referred to as dissection) is caused by the proximal tear of the aortic intima layer or the rupture and bleeding of the vasa vasorum in the aortic wall. The torn intima sheet extends forward or backward, promoting and continuing the separation of the aortic wall, forming true and false lumens. Once the false lumen ruptures, the patient may die in a very short time, and there is almost no possibility of rescue. It is a critical cardiovascular disease. The incidence of acute dissection can reach 3-5 / 100,000, and the incidence in the middle-aged population rises to 15-20 / 100,000. The average age of onset is 63 years old, and most of them are men (65%). Patients with acute dissection usually have no signs before the onset of the disease, and lack typical symptoms when they develop. Common clinical manifestations include sudden severe chest pain, back pain and high blood pressure, as well as dizziness, abdominal pain and limb ischemia caused by tearing of the intima to the branch artery. It is easy to be misdiagnosed or missed, delaying the best time for treatment. After the onset of acute dissection, the mortality rate increases by 1% to 3% per hour, the 24-hour mortality rate is as high as 21%, and the 7-day mortality rate is as high as 74%.

[0003] Thoracic endovascular aortic repair (TEVAR) is currently the preferred treatment for type B aortic dissection, with the advantages of less trauma, high success rate, rapid postoperative recovery, and definite efficacy. The first TEVAR was successfully performed in 1996. Over the decades of development and iteration, new surgical instruments and technologies have emerged in an endless stream, and treatment concepts have also changed accordingly. Evidence-based medicine based on large-scale clinical trials shows that compared with the best medical treatment, patients with complex dissection who receive TEVAR have better short-term and long-term prognosis and significant clinical benefits; compared with open surgery, TEVAR has better short-term prognosis and similar long-term prognosis. TEVAR mainly works by closing the proximal intimal rupture of the aorta, restoring positive blood flow in the true lumen, and promoting false lumen thrombosis and aortic remodeling. However, simply closing the proximal rupture leaves an imbalanced distribution of blood flow in the distal true and false lumens. In some patients, the distal aortic blood flow continues to flow backward into the false lumen, and the weak wall of the false lumen that is not full-thickness continues to expand and form tumors, that is, poor aortic remodeling or negative remodeling increases the risk of aortic rupture, leading to complications such as endoleak, new distal rupture, proximal retrograde type A dissection, and organ dysfunction. Improving aortic remodeling has become the key to further improving the overall prognosis of dissection. In-depth research on aortic remodeling after endovascular treatment of dissection, exploring indicators that effectively predict the effect of aortic remodeling, accurately identifying patients at high risk of aortic-related adverse events after surgery, and providing close follow-up and active intervention, thereby optimizing the effect of endovascular treatment, improving the prognosis of patients with dissection, and further reducing the risk of aortic-related death and adverse events are the key and difficulty in the current diagnosis and treatment of dissection.

[0004] In recent years, the development of multi-omics technologies represented by single-cell sequencing has brought breakthrough progress in the study of therapeutic targets for dissection. Existing studies mainly focus on the phenotypic transformation of macrophages and vascular smooth muscle cells (VSMC). A study found that systemic inflammation played an important role in the occurrence and development of dissection, emphasizing the importance of anti-inflammatory treatment in dissection, and confirmed that the specific inhibitory peptide drug mLR12 of Trem1+ macrophages can significantly reduce the aortic rupture rate in mice and improve the survival rate of model mice. In addition, a recent study found that different disease stages of dissection showed different pathological characteristics. Acute dissection showed a decrease in the contractile phenotype of VSMC and an increase in the synthetic phenotype. Further mechanism studies found that tumor necrosis factor (TNF) triggered the OXPHOS-AP-1 axis to promote VSMC phenotypic transformation. Targeting AP-1 can inhibit the phenotypic transformation of VSMC and alleviate the progression and rupture of dissection.

[0005] Many studies have reported that systemic inflammation is involved in the occurrence, development and outcome of dissection. The previous studies of this invention deeply explored the systemic remodeling of the immune microenvironment under pathological conditions of dissection and the key signals that are differentiated under normal and pathological conditions. It was found that macrophages associated with dissection phenotype can promote neutrophil activation, chemotaxis and degranulation by releasing chemokines, etc., inducing the formation of neutrophil extracellular traps (NETs), and further promoting the formation of aortic local inflammatory immune microenvironment. Targeting dissection-specific inflammatory activation sites and pathways, such as neutrophil extracellular traps (NETs) and / or specific CXC chemokine-receptor biological axis-related pathways, is expected to become an effective targeted treatment method to promote benign remodeling of dissected aorta. Blocking the formation of NETs and specific CXC chemokine-receptor biological axes can alleviate the progression and rupture of dissection, and can be used as a potential target for drug treatment. Summary of the invention

[0006] Based on the above research background, the present invention provides a method for blocking the formation of NETs and a specific CXC chemokine-receptor biological axis to alleviate the progression and rupture of dissection, improve the prognosis of patients with dissection, and achieve survival benefits for patients. Secondly, the present invention also provides a pharmaceutical composition that can prevent, treat, and alleviate the progression of aortic dissection.

[0007] The present invention includes the following technical solutions:

[0008] In a first aspect, the present invention provides a use of NETs and CXC chemokine-receptor biological axis as a target in at least one of the following:

[0009] a1) Use in the preparation and / or screening of drugs for preventing aortic dissection;

[0010] a2) Application in the preparation and / or screening of drugs for the treatment or auxiliary treatment of aortic dissection;

[0011] a3) Use in the preparation and / or screening of drugs for inhibiting the occurrence and / or development of aortic dissection.

[0012] The CXC chemokine-receptor biological axis described in the present invention is composed of a CXC chemokine and a CXC chemokine receptor, wherein the CXC chemokine is selected from one or a combination of two or more of CXCL2, CXCL3, and CXCL8; and the CXC chemokine receptor is selected from one of CXCR1 and CXCR2.

[0013] In a specific embodiment of the present invention, the CXC chemokine-receptor biological axis is selected from at least one of the following:

[0014] b1) CXCL2-CXCR1 biological axis;

[0015] b2) CXCL2-CXCR2 biological axis;

[0016] b3) CXCL3-CXCR1 biological axis;

[0017] b4) CXCL3-CXCR2 biological axis;

[0018] b5) CXCL8-CXCR1 biological axis;

[0019] b6) CXCL8-CXCR2 biological axis.

[0020] Preferably, the CXC chemokine-receptor biological axis is selected from one or a combination of two or more of the following: the CXCL3-CXCR1 biological axis, the CXCL3-CXCR2 biological axis, and the CXCL8-CXCR1 biological axis.

[0021] More preferably, the CXC chemokine-receptor biological axis is the CXCL3-CXCR2 biological axis.

[0022] In the most preferred embodiment of the present invention, the present invention provides a use of NETs and CXCL3-CXCR2 biological axis as targets in at least one of the following:

[0023] a1) Use in the preparation and / or screening of drugs for preventing aortic dissection;

[0024] a2) Application in the preparation and / or screening of drugs for the treatment or auxiliary treatment of aortic dissection;

[0025] a3) Use in the preparation and / or screening of drugs for inhibiting the occurrence and / or development of aortic dissection.

[0026] In a second aspect, the present invention provides a method for screening a candidate drug for preventing and / or treating aortic dissection or inhibiting the progression of aortic dissection, the method comprising at least one of the following:

[0027] c1) Using NETs as drug targets, searching for substances that can inhibit NETs formation and / or inhibit NETs activity and / or degrade NETs as candidate drugs;

[0028] c2) Using the CXC chemokine-receptor biological axis as a drug target, searching for substances that can neutralize and / or block the formation of the CXC chemokine-receptor biological axis and / or reduce the expression of the CXC chemokine-receptor biological axis as candidate drugs.

[0029] The CXC chemokine-receptor biological axis is as described in the first aspect of the present invention.

[0030] In the most preferred embodiment of the present invention, the CXC chemokine-receptor axis is the CXCL3-CXCR2 axis, and substances that can neutralize and / or block the formation of the CXCL3-CXCR2 axis and / or reduce the expression of the CXCL3-CXCR2 axis are preferably used as candidate drugs.

[0031] In a third aspect, the present invention provides a use of a NETs inhibitor and a CXC chemokine-receptor biological axis blocker in at least one of the following:

[0032] d1) Use in the preparation and / or screening of drugs for preventing aortic dissection;

[0033] d2) Use in the preparation and / or screening of drugs for the treatment or auxiliary treatment of aortic dissection;

[0034] d3) Use in the preparation and / or screening of drugs for inhibiting the occurrence and / or development of aortic dissection.

[0035] In the present invention, the NETs inhibitor includes a substance that inhibits the formation of NETs, ​​a substance that inhibits the activity of NETs, ​​or a substance that degrades NETs. The substance includes but is not limited to one or more of nucleic acid molecules, small molecule compounds, antibodies, peptides, proteins, gene editing vectors, lentiviruses, or adeno-associated viruses.

[0036] Preferably, the NETs inhibitor comprises a NETs formation inhibitor and / or a NETs degrader, wherein the NETs formation inhibitor is selected from Cl-amidine; and the NETs degrader is selected from DNase I.

[0037] In a specific embodiment of the present invention, the NETs inhibitor is selected from Cl-amidine, DNase I, or a combination of two or more thereof.

[0038] In a specific embodiment of the present invention, the NETs inhibitor is Cl-amidine.

[0039] In a specific embodiment of the present invention, the NETs inhibitor is DNase I.

[0040] In a specific embodiment of the present invention, the NETs inhibitor is a combination of Cl-amidine and DNase I.

[0041] In the most preferred embodiment of the present invention, the NETs inhibitor is Cl-amidine.

[0042] In the present invention, the CXC chemokine-receptor biological axis blocker includes a substance that neutralizes and / or blocks the formation of the CXC chemokine-receptor biological axis and / or a substance that reduces the expression of the CXC chemokine-receptor biological axis, and the substance includes one or more of a nucleic acid molecule, a small molecule compound, an antibody, a polypeptide, an enzyme, a gene editing vector, a lentivirus or an adeno-associated virus.

[0043] In a specific embodiment of the present invention, the substance capable of neutralizing and / or blocking the formation of the CXC chemokine-receptor biological axis includes proteases or nucleases that degrade CXC chemokines and / or CXC chemokine receptors, antibodies against CXC chemokines and / or CXC chemokine receptors, or their functional fragments.

[0044] In a specific embodiment of the present invention, the substance that reduces the expression of the CXC chemokine-receptor biological axis includes siRNA, shRNA or miRNA that knocks out or silences CXC chemokines and / or CXC chemokine receptors.

[0045] Preferably, the CXC chemokine-receptor biological axis blocker is an antibody or a functional fragment thereof against CXC chemokine and / or CXC chemokine receptor, wherein the CXC chemokine is selected from one or a combination of two or more of CXCL2, CXCL3, and CXCL8; and the CXC chemokine receptor is selected from one of CXCR1 and CXCR2.

[0046] More preferably, the CXC chemokine-receptor biological axis blocker is selected from one or a combination of two or more of an anti-CXCL3 antibody and an anti-CXCR2 antibody.

[0047] In the most preferred embodiment of the present invention, the CXC chemokine-receptor biological axis blocker is selected from anti-CXCR2 antibodies.

[0048] In a specific embodiment of the present invention, the anti-CXCL3 antibody and the anti-CXCR2 antibody can be purchased through commercial channels.

[0049] The technical solution provided by the present invention has the following technical contributions:

[0050] The present invention found that inhibiting NETs can effectively reduce the expression of CitH3, while significantly reducing aortic dilatation, reducing the average value of the maximum diameter of the aorta, keeping the elastic fibers intact, and significantly reducing the mortality rate of aortic dissection. Therefore, the present invention proposes that NETs inhibitors have the effect of preventing, treating and hindering the occurrence and development of aortic dissection.

[0051] The present invention creatively discovered that, compared with NETs degraders, NETs formation inhibitors have a better improvement effect on aortic dissection. The present invention discovered that intervening in NETs before they are formed is more effective in preventing and treating aortic dissection than degrading NETs after they have been formed.

[0052] The present invention finds that blocking the CXC chemokine-receptor biological axis can also prevent, treat and hinder the occurrence and development of aortic dissection. At the beginning of the study, the inventors obtained 6 CXC chemokine-receptor biological axes related to AD through Cellphone DB analysis and screening. Through in-depth research, the inventors preferred that 3 of the CXC chemokine-receptor biological axes were significantly correlated with AD, among which the CXCL3-CXCR2 biological axis is the biological axis with the greatest potential to become a target. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 Effects of NETs inhibitors on AD, A) Experimental design flow chart; B) Statistical chart of the incidence and mortality of aortic dissection in mice; C) Mouse survival rate-time relationship curve; D) Mouse echocardiography results; E) Aortic diameter measured by mouse cardiac ultrasound; F) Statistical chart of maximum aortic diameter; G) Statistical chart of average wall thickness; H) Statistical chart of average membrane thickness; I) Statistical chart of elastin degradation grade.

[0054] Figure 2 Cellphone DB analysis of ligand-receptor interactions between macrophages and neutrophils.

[0055] Figure 3 The CXCL3-CXCR2 biological axis is highly expressed in AD. A) Cellchat cell communication analysis shows that neutrophils in the dissection interact with other cells; B) Cellchat cell communication analysis shows the ligand-receptor interaction between neutrophils and macrophages; C) Fluorescence staining of human aortic dissection tissue shows co-localization of CXCL3 and CD68 (macrophage marker); D) Fluorescence staining of human aortic dissection tissue shows co-localization of CXCR2 and MPO (neutrophil marker); E) Fluorescence staining of mouse aortic dissection tissue Staining showed co-localization of CXCL3 and F4 / 80 (macrophage marker); F) Fluorescence staining of mouse aortic dissection tissue showed co-localization of CXCR2 and Ly6G (neutrophil marker); G) Correlation between the number of CXCL3-positive macrophages and CXCR2-positive neutrophils in aortic dissection tissue; H) Correlation between the number of CXCL3-positive macrophages and the degree of elastin degradation in the aortic wall in aortic dissection tissue; I) Correlation between the number of CXCR2-positive neutrophils and the degree of elastin degradation in the aortic wall in aortic dissection tissue.

[0056] Figure 4 Effects of CXCL3-CXCR2 biological axis blockers on AD, A) Experimental design flow chart; B) Statistical graph of the incidence and mortality of aortic dissection in mice; C) Mouse survival rate-time relationship curve; D) Statistical graph of maximum aortic diameter; E) Statistical graph of average wall thickness; F) Statistical graph of average membrane thickness; G) Statistical graph of elastin degradation grade. DETAILED DESCRIPTION

[0057] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only some embodiments of the present invention, not all. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0058] Explanation of terms

[0059] BAPN: β-aminopropionitrile, β-aminopropionitrile, is a lysyl oxidase inhibitor that destroys the integrity of the arterial wall structure by inhibiting the cross-linking of collagen and elastin. Continuous administration of BAPN water to C57 mice can cause degeneration of the arterial media, leading to aortic dissection and aneurysm formation. All aortic dissection models used in the present invention are verified by HE staining of aortic sections, and the formation of true and false aortic cavities is observed, and the model mice with aortic aneurysms are eliminated.

[0060] Cl-amidine: Cl-amidine hydrochloride, a PAD4 inhibitor. PAD4 is the enzyme responsible for histone citrullination during NETosis and is also an enzyme necessary for the formation of NETs. Therefore, Cl-amidine hydrochloride has the effect of inhibiting the formation of NETs and is an inhibitor of NETs formation.

[0061] DNase I: Deoxyribonuclease I, whose Chinese name is deoxyribonuclease I, can promote the degradation of DNA released into the extracellular space and plasma after the formation of NETs, ​​and has the effect of partially promoting the degradation of NETs.

[0062] Anti-CXCL3: refers to an antibody against chemokine CXCL3. In a specific embodiment of the present invention, the Anti-CXCL3 is purchased from R&D systems.

[0063] Anti-CXCR2: refers to an antibody against chemokine receptor CXCR2. In a specific embodiment of the present invention, the Anti-CXCR2 is purchased from R&D systems.

[0064] The theory proposed by the present invention is supported by the following experimental data:

[0065] 1. Application of NETs in the treatment of aortic dissection or inhibition of its progression

[0066] 1. Research subjects

[0067] (1) Experimental animals: 3-week-old C57 / BL 6J male SPF (Specific-pathogen free) mice were purchased from Shanghai Weitong Lihua Experimental Animal Co., Ltd. and raised in the Central Laboratory of Zhongshan Hospital Affiliated to Fudan University. They were housed in a constant temperature of 25-27°C and constant humidity of 45-50% in a specific pathogen-free (SPF) environment with 12-h light / dark cycles and free access to standard food pellets and drinking water.

[0068] (2) Preliminary experiment to explore the drug concentration of NETs inhibitors: 3-week-old C57 / BL 6J male SPF mice were purchased and numbered. The mice were randomly divided into 4 groups using Excel, named Saline group, BAPN group, Cl-amidine1 group, and Cl-amidine2 group. BAPN was dissolved in pure water to form a 5 mg / mL solution. The mice in the BAPN group, Cl-amidine1 group, and Cl-amidine2 group were fed with the BAPN solution to form an aortic dissection model, and the Saline group was fed with the same volume of normal saline.

[0069] The mice were grouped as follows:

[0070] ①Saline group: 8 mice;

[0071] ②BAPN group: 8 rats;

[0072] ③Cl-amidine1 group: 8 mice, Cl-amidine concentration was 10 mg / kg;

[0073] ④Cl-amidine2 group: 8 mice, Cl-amidine concentration was 20 mg / kg;

[0074] During the 4th to 6th week of age, mice in the Cl-amidine1 and Cl-amidine2 groups received intraperitoneal injection of Cl-amidine once a day at a fixed time until the mice died or the experimental end point, with drug concentrations of 10 mg / kg and 20 mg / kg, respectively. At the same time, mice in the BAPN and Saline groups received intraperitoneal injection of normal saline instead.

[0075] (3) Formal experimental grouping: The experimental process is as follows Figure 1As shown in A, 3-week-old C57 / BL 6J male SPF mice were purchased and numbered, and the mice were randomly divided into 5 groups using Excel, namely Ctrl group, BAPN group, Cl-amidine group, DNase I group and Combo group. The mice in the BAPN group, Cl-amidine group, DNase I group and Combo group were fed with 5 mg / mL BAPN solution to form an aortic dissection model, and the Ctrl group was fed with the same volume of normal saline.

[0076] The mice were grouped as follows:

[0077] ①Ctrl group: 12;

[0078] ②BAPN group: 12 rats;

[0079] ③Cl-amidine group: 12 mice, Cl-amidine concentration was 10 mg / kg (the concentration determined by preliminary experiments);

[0080] ④DNase I group: 12 mice, DNase I concentration was 5 mg / kg;

[0081] ⑤Combo group: 12 mice, Cl-amidine concentration was 10 mg / kg, DNase I concentration was 5 mg / kg.

[0082] During the 4th to 6th week of age, mice in the Cl-amidine, DNase I, and Combo groups received intraperitoneal injections of Cl-amidine and DNase I once a day at the same fixed time until the mice died or the end of the experiment. Mice in the BAPN and Ctrl groups were injected with normal saline instead. Before administration, each mouse was examined by echocardiography and the aortic diameter was measured.

[0083] (4) Experimental animal operation procedures

[0084] ① Mouse serial number marking: Grasp the mouse's neck and back skin with one hand, turn the palm of your hand so that the mouse's belly is facing up and facing you, with its limbs naturally open. The left and right toes of the mouse are defined as left when the mouse's belly is facing the operator, and right and left are the standard of the operator. The lower left and lower right toes of the mouse are marked as 1-10, and the upper left and upper right toes are marked as 20-90. Cutting the corresponding toe bones represents the corresponding number.

[0085] ② Mouse body weight measurement: Weigh the mice every 3 days, measure twice each time and take the average value, and determine the amount of drug injected each time by weighing.

[0086] ③ Intraperitoneal injection: Grab the mouse's tail with one hand and pull it back, and use the thumb and index finger of the other hand to grab the fur on the back of the mouse's head, and flip it over so that the abdomen is facing upward. With the needle tip of the syringe facing upward, insert it parallel to the skin, and then insert the syringe into the abdomen at a 45-degree angle. Inject the drug after you feel that the needle tip can move. When a mouse is injected with two drugs at the same time, inject the two drugs on the left and right sides of the abdomen respectively. No anesthesia is used during the injection of drugs: the injection volume of the drug is small, and the experimenter is skilled in the operation of intraperitoneal injection, so the animals suffer less pain even without anesthesia.

[0087] ④ Animal experiment endpoints and mouse treatment measures: The experimental endpoints include the death of mice during the experiment. The surviving mice were uniformly killed by intraperitoneal injection of sodium pentobarbital at the end of the fifth week of continuous feeding. All mice were required to be dissected to find out the cause of death, and the mouse aorta was preserved. The remaining tissues of the mice were packaged and sent to a professional experimental animal treatment center for treatment.

[0088] ⑤ Collection of mouse aorta: Sodium pentobarbital anesthesia, supine fixation of limbs. Disinfect the chest, open the chest cavity of the mouse, cut off the right atrial appendage, insert the needle into the left ventricle from the apex of the heart, inject about 5 ml of PBS flushing solution, free and remove the heart together with the starting section of the ascending aorta to the bifurcation of the left and right iliac branches, a part of which is fixed with paraformaldehyde and preserved, embedded in wax blocks, and sliced ​​for observation; a part is preserved in liquid nitrogen to provide tissue support for subsequent research.

[0089] 2. Research Methods

[0090] Continuous variables were expressed as means (SDs) with standard deviations or medians (IQRs) with interquartile ranges. Student's t test or Mann-Whitney U test was used for continuous variables, and Pearson's chi-square test or Fisher's exact test was used for categorical variables. Kolmogorov-Smirnov test for normal distribution was used. Odds ratios (OR) with 95% confidence intervals (CI) were calculated by logistic regression. Survival analysis was performed using Kaplan-Meier curves and log-rank tests. P < 0.05 was considered statistically significant.

[0091] 3. Research Results

[0092] Before administration, the mice were examined by echocardiography, and the maximum diameter of the aorta and other parameters of each mouse were measured. At the end of the experiment, 66.7% (8 / 12) of the mice in the BAPN group developed aortic dissection, of which 50% (6 / 12) died before the end of the experiment due to aortic rupture, and the first mouse died on the 9th day. In the Cl-amidine group, 50.0% (6 / 12) of the mice developed aortic dissection, of which 16.7% (2 / 12) died before the end of the experiment due to aortic rupture. In the DNase I group, 66.7% (8 / 12) of the mice developed aortic dissection, of which 50.0% (6 / 12) died before the end of the experiment due to aortic rupture. ( Figure 1 B. Figure 1 C). At the end of the experiment, the survival rate of mice in the Cl-amidine group was significantly improved (Log-rank test, P<0.05). The survival rate of mice in the DNase I group was not statistically significant compared with that in the BAPN group. The NETs formation inhibitor (Cl-amidine) has a better effect on improving the mortality of aortic dissection than the NETs degrader (DNase I).

[0093] Mouse echocardiography and statistical graphs showed that the diameter of the aorta with dissection in the BAPN group was enlarged, while the aorta dilation in the Cl-amidine group was significantly reduced, the average value of the maximum diameter of the aorta was reduced, and the difference was statistically significant. The elastic fibers remained almost intact. The average value of the maximum diameter of the aorta in the DNase I group was slightly reduced, but the difference was not statistically significant. There was elastic fiber rupture and false lumen thrombosis in the aorta, resulting in partial compression of the true lumen ( Figure 1 DI). Compared with the group of Cl-amidine and DNase I co-administered, the average value of the maximum diameter of the aorta in the Cl-amidine administration group was more significantly reduced. The most preferred NETs inhibitor of the present invention is Cl-amidine administered alone.

[0094] In summary, the present invention confirms through the mouse aortic dissection model that specific inhibition of NETs formation can effectively alleviate the progression of dissection, reduce the risk of death caused by aortic rupture, and promote benign aortic remodeling, showing good effects and broad application prospects, and is expected to be used in clinical treatment as a potential target for controlling the progression of dissection.

[0095] II. Application of CXC chemokine-receptor biological axis in treating aortic dissection or inhibiting the progression of aortic dissection

[0096] (1) Screening of CXC chemokine-receptor biological axis related to AD

[0097] Cellphone DB was used to analyze the ligand-receptor interactions between macrophages and neutrophils. Six CXC chemokine-receptor biological axes related to AD were screened, namely, CXCL2-CXCR1 biological axis, CXCL2-CXCR2 biological axis, CXCL3-CXCR1 biological axis, CXCL3-CXCR2 biological axis, CXCL8-CXCR1 biological axis and CXCL8-CXCR2 biological axis ( Figure 2 ).

[0098] Furthermore, the inventors screened out three CXC chemokine-receptor biological axes that are significantly associated with AD, namely the CXCL3-CXCR1 biological axis, the CXCL3-CXCR2 biological axis, and the CXCL8-CXCR1 biological axis ( Figure 3 A and 3B), during the research, the inventors found that the CXCL3-CXCR2 biological axis is more closely related to aortic dissection and is expected to become a potential target for controlling the progression of aortic dissection ( Figure 3 ).

[0099] (2) The role of CXCL3-CXCR2 biological axis blockers in the treatment or inhibition of aortic dissection

[0100] 1. Research subjects

[0101] (1) Experimental animals: 3-week-old C57 / BL 6J male SPF (Specific-pathogen free) mice were purchased from Shanghai Weitong Lihua Experimental Animal Co., Ltd. and raised in the Central Laboratory of Zhongshan Hospital Affiliated to Fudan University. They were housed in a constant temperature of 25-27°C and constant humidity of 45-50% in a specific pathogen-free (SPF) environment with 12-h light / dark cycles and free access to standard food pellets and drinking water.

[0102] Experimental grouping: Experimental process is as follows Figure 4 As shown in A, 3-week-old C57 / BL 6J male SPF mice were purchased and numbered, and the mice were randomly divided into 5 groups using Excel, namely Ctrl group, BAPN group, IgG group, Anti-CXCL3 group, and Anti-CXCR2 group. The mice in the BAPN group, IgG group, Anti-CXCL3 group, and Anti-CXCR2 group were fed with 5 mg / mL BAPN solution to form an aortic dissection model, and the Ctrl group was fed with the same volume of normal saline.

[0103] The mice were grouped as follows:

[0104] ①Ctrl group: 12;

[0105] ②BAPN group: 12 rats;

[0106] ③IgG group: 12 mice;

[0107] ④Anti-CXCL3 group: 12 mice, Anti-CXCL3 concentration was 2 mg / kg;

[0108] ⑤Anti-CXCR2 group: 12 mice, Anti-CXCR2 concentration was 2 mg / kg.

[0109] During the 4th to 6th week of age, mice in the IgG, Anti-CXCL3, and Anti-CXCR2 groups received intraperitoneal injections of IgG, Anti-CXCL3, and Anti-CXCR2 drugs at the same fixed time every 3 days until the mice died or the end of the experiment. Mice in the BAPN and Ctrl groups were injected with normal saline instead. Each mouse was examined by echocardiography before administration, and the aortic diameter was measured.

[0110] The experimental animal operation procedures and research methods are shown in the above-mentioned NETs mouse experiment section.

[0111] 2. Research Results

[0112] By the end of the experiment, 66.7% (8 / 12) of the mice in the BAPN group developed dissection, of which 58.3% (7 / 12) died before the end of the experiment due to aortic rupture. In the IgG group, 58.3% (7 / 12) of the mice developed aortic dissection, of which 50% (6 / 12) died before the end of the experiment due to aortic rupture. In the Anti-CXCL3 group, 58.3% (7 / 12) of the mice developed dissection, of which 25% (3 / 12) died before the end of the experiment due to aortic rupture. In the Anti-CXCR2 group, 50% (6 / 12) of the mice developed dissection, of which 16.7% (2 / 12) died before the end of the experiment due to aortic rupture. Figure 4 B. Figure 4 C). At the end of the experiment, the survival rate of mice in the Anti-CXCL3 and Anti-CXCR2 administration groups was significantly improved compared with the BAPN group, and the mortality rate of mice in the Anti-CXCR2 administration group was the lowest. According to the echocardiogram, it can be seen that the average value of the maximum diameter of the aorta of mice in the Anti-CXCR2 administration group decreased most significantly, which was statistically different from the BAPN group. The above experimental results show that on the basis of the significant correlation between the CXCL3-CXCR2 biological axis and aortic dissection, the technicians of the present invention unexpectedly found that anti-CXCR2 antibodies are more beneficial for the treatment and inhibition of the progression of aortic dissection.

[0113] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A method for using a NETs and CXC chemokine-receptor biological axis as a target in at least one of the following: a1) Use in the preparation and / or screening of drugs for preventing aortic dissection; a2) Application in the preparation and / or screening of drugs for the treatment or auxiliary treatment of aortic dissection; a3) Use in the preparation and / or screening of drugs for inhibiting the occurrence and / or development of aortic dissection. The CXC chemokine-receptor biological axis described in the present invention is composed of a CXC chemokine and a CXC chemokine receptor, wherein the CXC chemokine is selected from one or a combination of two or more of CXCL2, CXCL3, and CXCL8; and the CXC chemokine receptor is selected from one of CXCR1 and CXCR2.

2. The use according to claim 1, characterized in that: The CXC chemokine-receptor biological axis is selected from at least one of the following: b1) CXCL2-CXCR1 biological axis; b2) CXCL2-CXCR2 biological axis; b3) CXCL3-CXCR1 biological axis; b4) CXCL3-CXCR2 biological axis; b5) CXCL8-CXCR1 biological axis; b6) CXCL8-CXCR2 biological axis.

3. The use according to claim 2, characterized in that: The CXC chemokine-receptor biological axis is selected from one or a combination of two or more of the following: the CXCL3-CXCR1 biological axis, the CXCL3-CXCR2 biological axis, and the CXCL8-CXCR1 biological axis.

4. The use according to claim 3, characterized in that: The CXC chemokine-receptor biological axis is the CXCL3-CXCR2 biological axis.

5. A method for screening a candidate drug for preventing and / or treating aortic dissection or inhibiting the progression of aortic dissection, the method comprising at least one of the following: c1) Using NETs as drug targets, searching for substances that can inhibit NETs formation and / or inhibit NETs activity and / or degrade NETs as candidate drugs; c2) Using the CXC chemokine-receptor axis as a drug target, searching for substances that can neutralize and / or block the formation of the CXC chemokine-receptor axis and / or reduce the expression of the CXC chemokine-receptor axis as candidate drugs; in, The CXC chemokine-receptor biological axis is as described in claim 1.

6. Use of a NETs inhibitor and a CXC chemokine-receptor biological axis blocker in at least one of the following: d1) Use in the preparation and / or screening of drugs for preventing aortic dissection; d2) Use in the preparation and / or screening of drugs for the treatment or auxiliary treatment of aortic dissection; d3) Use in the preparation and / or screening of drugs for inhibiting the occurrence and / or development of aortic dissection; The NETs inhibitors include substances that inhibit NETs formation, substances that inhibit NETs activity, or substances that degrade NETs, ​​and the substances include but are not limited to one or more of nucleic acid molecules, small molecule compounds, antibodies, peptides, proteins, gene editing vectors, lentiviruses, or adeno-associated viruses; The CXC chemokine-receptor biological axis blocker includes a substance that neutralizes and / or blocks the formation of the CXC chemokine-receptor biological axis and / or a substance that reduces the expression of the CXC chemokine-receptor biological axis, and the substance includes one or more of a nucleic acid molecule, a small molecule compound, an antibody, a polypeptide, an enzyme, a gene editing vector, a lentivirus or an adeno-associated virus.

7. The use according to claim 6, characterized in that: The NETs inhibitor includes a NETs formation inhibitor and / or a NETs degrader, wherein the NETs formation inhibitor is selected from Cl-amidine; the NETs degrader is selected from DNase I; The substances capable of neutralizing and / or blocking the formation of the CXC chemokine-receptor biological axis include proteases or nucleases that degrade CXC chemokines and / or CXC chemokine receptors, antibodies against CXC chemokines and / or CXC chemokine receptors, or functional fragments thereof; The substance that reduces the expression of the CXC chemokine-receptor biological axis includes siRNA, shRNA or miRNA that knocks out or silences CXC chemokines and / or CXC chemokine receptors.

8. The use according to claim 7, characterized in that: The CXC chemokine-receptor biological axis blocker is an antibody or a functional fragment thereof against CXC chemokines and / or CXC chemokine receptors, wherein the CXC chemokine is selected from one or a combination of two or more of CXCL2, CXCL3, and CXCL8; and the CXC chemokine receptor is selected from one of CXCR1 and CXCR2.

9. The use according to claim 8, characterized in that: The NETs inhibitor is one of Cl-amidine and DNase I or a combination of two thereof; the CXC chemokine-receptor biological axis blocker is one of anti-CXCL3 antibodies and anti-CXCR2 antibodies or a combination of two thereof.

10. The use according to claim 9, characterized in that: The NETs inhibitor is Cl-amidine; the CXC chemokine-receptor biological axis blocker is selected from anti-CXCR2 antibodies.